Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01972-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Zheng Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Lapatinib, Interleukin-17, Antiviral Agents, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National first-class undergraduate major construction point (Biotechnology), National Natural Science Foundation of China.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infections in infants and young children worldwide. Safe and effective treatments for RSV remain limited. In this investigation, we screened more than 100 anti-influenza compounds from a small-molecule library using an A549 cell model. Among these drugs, lapatinib emerged as a promising candidate and demonstrated potent anti-RSV activity along with low cytotoxicity. Lapatinib not only significantly suppressed RSV replication in vitro but also markedly reduced viral proliferation and mitigated inflammatory lung injury in a BALB/c female mouse model. Mechanistic studies revealed that lapatinib inhibited RSV replication through the downregulation of interleukin-17 (IL-17). This effect was antagonized upon IL-17 overexpression, confirming the pivotal role of this cytokine. We further proposed that lapatinib exerted its antiviral effect by targeting ErbB1 and ErbB2 receptors, thereby disrupting IL-17–mediated viral propagation. These findings provide both novel mechanistic insights and a compelling therapeutic direction for the treatment of RSV infection。.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Anhui Medical University, Hefei, Anhui, China.
- Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
- Department of Neurosurgery, Anhui Public Health Clinical Center (North District, the First Affiliated Hospital of Anhui Medical University), Hefei, Anhui, China.
- The Institute of Clinical Virology, Anhui Medical University, Hefei, Anhui, China.
ORCID-Profile: Qi Tang, Mingwei Chen, Shenghai Huang
Förderung
- National Key Research and Development Program of China
- National first-class undergraduate major construction point (Biotechnology)
- National Natural Science Foundation of China
- Major Project of Natural Science Research of Anhui Education Department
Zitieren
APA
Sun, Z., Huang, Y., Guo, R., Jiang, T., Chen, Q., Zhang, X., Liu, J., Tang, Q., Chen, M., & Huang, S. (2026). Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01972-25
Vancouver
Sun Z, Huang Y, Guo R, Jiang T, Chen Q, Zhang X, et al. Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01972-25
BibTeX
@article{Sun2026,
author = {Sun, Zheng and Huang, Yixuan and Guo, Rui and Jiang, Tao and Chen, Qingru and Zhang, Xinyu and Liu, Jiling and Tang, Qi and Chen, Mingwei and Huang, Shenghai},
title = {Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01972-25}
}
EUVIMED